One capsule, four clocks
Pages like this one usually settle on a single story. Blood flow, nearly always,
because a diagram of it is easy to draw. The reality here is messier: four distinct
processes are in play, their timescales look nothing like each other, and the slowest
of them outlasts the stretch most people give any supplement.
Sorting out which is which is what separates a fair test of the product from a
half-empty bottle abandoned in week two.
Same day — theanine beside caffeine
Begin here, because nothing else in the capsule does a thing on day one. Green tea
extract carries L-theanine along with natural caffeine in a small amount, and that
pair has been measured on attention-switching tasks a couple of hours after a dose.
Haskell's 2008 crossover is the reference, and the combination beat either compound
taken by itself.
Two caveats belong in the same breath. What moved was attention, a separate system
from recall. And the size of it is modest: what the paper describes is a lower cost to
holding concentration, not a surge anybody would mistake for an energy drink. The
caffeine dose sits under what a cup of coffee delivers.
Week six — the circulation case
Ginkgo leaf supplies flavone glycosides and terpene lactones, and the work on them
concerns how blood travels through the body's narrowest vessels. Kaschel ran the
best-known controlled test of it in 2011: 188 healthy adults between forty-five and
fifty-six, 240 mg a day of a standardised extract, six weeks on it, and stronger
recall for appointments they had agreed to attend.
Now read the qualifier with equal attention. Recognition memory in that same trial
showed no advantage whatsoever. One kind of recall shifted; another did not.
Zoom out and the picture gets less flattering. The GEM study under DeKosky,
published in JAMA in 2008, tracked over three thousand older adults across roughly six
years and reported no drop in dementia incidence. Snitz, working the same cohort a
year later, found that broader cognitive decline had not slowed either. Neither result
has been overturned, and quoting the 2011 trial while omitting them gives you half of
what the literature says.
Month twelve — pigment that has to build up
Marigold supplies lutein and zeaxanthin, which gather in retinal and nerve tissue
on a schedule the tissue controls rather than the dose. Hammond's 2017 trial ran
12 mg daily for a full twelve months and recorded an attention benefit among
older adults, with fifty-one participants still analyzable at the finish.
No shortcut exists. A larger dose does not compress that timeline, because what
limits uptake is the tissue itself and not the level in your blood.
Month eighteen — oxidative load
Curcumin, EGCG and lutein all push against oxidative stress, one of the sturdier
accounts of how nerve tissue degrades across decades. It is also a process you cannot
feel. Nothing about it produces a sensation of any kind.
Small's 2018 trial is the one to name: forty adults, aged 51 to 84, on an absorbable
curcumin, for eighteen months, ending ahead of placebo on composites for memory and
attention. Twenty people to an arm makes it a pilot rather than a conclusion, and
eighteen months is a long bet to place on a pilot.
The two with no mechanism to describe
For bamboo silica and D-Glucosamine Sulfate the cognitive evidence base is empty.
Not sparse — empty. Silicon's established role sits in bone and connective
tissue, which is the subject of Jugdaohsingh's 2007 review. D-Glucosamine turns up on
joint-care shelves, and the biggest dataset carrying its name, Ma's 2019 paper in the
BMJ, examined cardiovascular outcomes.
Both earn their place as a mineral and a structural input. Printing that beats
inventing a mechanism for them.
The limits of all of the above. Every mechanism here comes out of
published papers, and none of them is a forecast about your next month. Evidence for
one ingredient on its own is not evidence for a finished product, and the finished
formula has never been trialled as a whole. The reported effects are small, they
surface over weeks and months, and in each study named above a share of participants
recorded no change. Group averages have never forecast one person.
